Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
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
dZY0r6Mb26EVCwuL
